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Background: To examine empirically whether the mean difference (MD) or the standardised mean difference
(SMD) is more generalizable and statistically powerful in meta-analyses of continuous outcomes when the same
unit is used.
Methods: From all the Cochrane Database (March 2013), we identified systematic reviews that combined 3 or
more randomised controlled trials (RCT) using the same continuous outcome. Generalizability was assessed using
the I-squared (I2) and the percentage agreement. The percentage agreement was calculated by comparing the MD
or SMD of each RCT with the corresponding MD or SMD from the meta-analysis of all the other RCTs. The statistical
power was estimated using Z-scores. Meta-analyses were conducted using both random-effects and fixed-effect
models.
Results: 1068 meta-analyses were included. The I2 index was significantly smaller for the SMD than for the MD
(P < 0.0001, sign test). For continuous outcomes, the current Cochrane reviews pooled some extremely heterogeneous
results. When all these or less heterogeneous subsets of the reviews were examined, the SMD always showed a greater
percentage agreement than the MD. When the I2 index was less than 30%, the percentage agreement was 55.3%
for MD and 59.8% for SMD in the random-effects model and 53.0% and 59.8%, respectively, in the fixed effect
model (both P < 0.0001, sign test). Although the Z-scores were larger for MD than for SMD, there were no differences
in the percentage of statistical significance between MD and SMD in either model.
Conclusions: The SMD was more generalizable than the MD. The MD had a greater statistical power than the SMD
but did not result in material differences.Background
A meta-analysis aggregates indexes of effectiveness of in-
dividual trials into one pooled estimate. When the out-
come of interest is a dichotomous variable, the commonly
used effect sizes include the odds ratio (OR), the relative
risk (RR), and the risk difference (RD). When the outcome
is a continuous variable, then the effect size is commonly
represented as either the mean difference (MD) or the
standardised mean difference (SMD) [1].
The MD is the difference in the means of the treat-
ment group and the control group, while the SMD is the* Correspondence: n.takeshima@gmail.com
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article, unless otherwise stated.MD divided by the standard deviation (SD), derived
from either or both of the groups. Depending on how
this SD is calculated, the SMD has several versions such,
as Cohen's d [2], Glass's Δ [3], and Hedges' g [4].
When the outcome is measured in different units
across trials, then we have no other choice but to use
the SMD to combine the outcomes in the meta-analyses.
On the other hand, when the outcome is measured in
the same unit in every trial, theoretically, we can use
either the MD or the SMD. In this latter case, there cur-
rently appears to be no unanimous agreement about
which effect size is preferable, and different textbooks of
meta-analyses provide differently nuanced recommenda-
tions about the selection of the appropriate effect size
for continuous variables.tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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Reviews of Interventions [1], the “selection of summary
statistics for continuous data is principally determined
by whether studies all report the outcome using the
same scale when the MD can be used.” The American
Psychological Association (APA) Task Force on Statis-
tical Inference maintains that “if the units of measure-
ment are meaningful on a practical level (e.g. number of
cigarettes smoked per day), then we usually prefer a MD
to a SMD” [5]. Egger et al. writes that “the overall treat-
ment effect [in terms of SMD] can also be difficult to in-
terpret as it is reported in units of standard deviation
rather than in units of any of the measurement scales
used in review” [6].
On the other hand, there are also authors who recom-
mend the SMD along with or over the MD. The APA Pub-
lication Manual suggests that it can often be valuable to
report not only the MD but also the SMD [7]. Borenstein,
in his “Introduction to Meta-Analysis” [8], wrote that if
the unit is unfamiliar, the SMD serves as an easy way to
judge the magnitude of the effect, thanks to the general
rules of thumb described by Cohen that suggest that an
SMD of 0.2 represents a “small” effect, an SMD of 0.5 rep-
resents a “medium” effect, and an SMD of 0.8 represents a
“large” effect [2]. For example, when you read that a treat-
ment group’s mean post-treatment score on scale X was
10 points higher than that of a control group, there is no
way of appreciating how much a difference this actually
represents unless you are very familiar with the scale that
is being used. But if the difference is expressed in terms of
SMD as corresponding to an effect size of 0.5, for ex-
ample, you can understand that it represents a moderate
effectiveness in comparison with the control. In fact, Tian
et al. noted that the SMD does not depend on the unit of
measurement, and therefore the SMD has been widely
used as a measure of intervention effect in many applied
fields [9].
The preferability of the MD or the SMD can be exam-
ined from three aspects. First, which of the MD or the
SMD is clinically more interpretable? The above-
summarised arguments made by different authors seem
to concern mainly this aspect. Second, which of the MD
or the SMD is more generalizable (as any summary
index should have a good generalizability so that it can
be applied to the next group of patients) [10]? Third,
which of the MD or the SMD is statistically more
powerful (as we expect meta-analyses to provide as pre-
cise an estimate of the treatment effect as possible and
to be as sensitive as possible to differences among
treatments)?
To the best of our knowledge, no systematic assess-
ment focusing on the second or third aspects of the MD
and the SMD has been conducted. The objective of this
research was, therefore, to examine empirically whichindex is more generalizable and statistically powerful in
meta-analyses when the same unit is used: MD or SMD?
Methods
Selection of meta-analyses
We included the following intervention meta-analyses
from the Cochrane Database of Systematic Reviews
(March 31, 2013) [11,12].
1. The outcome of the meta-analyses was a continuous
outcome in the same unit.
2. There were at least three studies contributing to
that continuous outcome in question, because we
need at least three studies in order to calculate the
percentage agreement that we defined as one of our
outcome (see below).
3. If there were two or more outcomes that met the
above criteria, we selected the outcome that
contained the greatest number of studies in the
review. If there were 2 or more such outcomes, we
chose the outcome reported for the greatest number
of patients. If the numbers of the patients were the
same, we selected the outcome that appeared first in
the review.
We excluded the outcomes reported in sensitivity
analyses or subgroup analyses.
Search methods and data extraction
We searched the Cochrane Database of Systematic
Reviews (March 31, 2013) using the term “mean differ-
ence” in all fields to identify all meta-analyses possibly
meeting the above eligibility criteria.
One author examined all the meta-analyses identified
using the above search methods to decide whether the
meta-analysis met our inclusion criteria and chose which
outcome to focus on. In order to evaluate the reliability
of the selections, we randomly selected 100 out of the
original set of meta-analyses and the other authors ex-
amined the reliability of these selections. We then calcu-
lated the kappas for these selections.
Outcomes
To look at generalizability, we examined (i) the I-squared
(I2) index and (ii) the percentage agreement. To compare
statistical power, we examined (iii) the Z-score.
(i) I2 index
The I2 index represents the degree of heterogeneity
across studies in meta-analyses [13]. It ranges from
0% to 100% and the following rough rule of thumb
has been proposed [1]:
0% to 40%: might not be important
30% to 60%: may represent moderate heterogeneity
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heterogeneity
75% to 100%: considerable heterogeneity.
Because more heterogeneous results are expected to
show less generalizability to similar populations, we
examined the I2 index of each meta-analysed MD
and SMD. We used the sign test to compare the I2
values for the MD and the SMD.
(ii) Percentage agreement
One study was extracted from each meta-analysis.
The MD and the SMD of that individual study were
then compared with the meta-analytically pooled
MD and the SMD of the remaining studies.
Agreement was defined when the point estimate of
the MD or the SMD of the individual study was
included within the 95% confidence interval of the
pooled MD or SMD of the remaining studies [10].
This procedure was repeated for all the studies, and
the overall percentage agreement was calculated. We
calculated two percentage agreement figures for each
meta-analysis, using the random-effects model [14]
or the fixed-effect model [15] for the meta-analysis.
In each model, we compared the percentage
agreement of the MD with that of the SMD
using the sign test.
(iii) Z-score
We also examined the Z-score or each meta-analysis in
order to examine possible differences in the statistical
power between the MD and the SMD using the sign
test. In addition, we compared the MD or SMD values
that were judged to be statistically significant at a
conventional level (P < 0.05) using the McNemar test.
In order to calculate the percentage agreements, the
I2 statistics, and the P-value for the treatment effectFigure 1 Flowchart for selection of meta-analysis.between the MD and the SMD, we used the inverse
variance method meta-analyses that are included in
SAS, Ver. 9.3 (SAS Institute Inc.). We defined SMD as
Hedges’ adjusted g to remove any upward bias that
might have arisen because of small sample sizes [16].Results
Search results
Figure 1 describes the process of our search. There were
5418 reviews in the Cochrane Database of Systematic
Reviews (March 31, 2013). When we searched the data-
base using the term “mean difference” in all the texts,
3961 reviews were selected. Of these, 1068 reviews met
our eligibility criteria. The main reason why the reviews
were excluded was that the outcome of the meta-
analyses contained two or fewer studies. Among the
1068 meta-analyses in our dataset, only 47 (4.4%) meta-
analyses reported SMD, and 1021 (95.6%) meta-analyses
reported MD. In order to confirm the reliability of this
identification, two authors independently examined 100
reviews that were randomly selected from the 3961 re-
views. The kappa was 0.90.
The median number of the studies contributing to
each outcome was 5 (interquartile range: 3 to 8). The
median total of participants used to determine the out-
come was 489 (interquartile range: 218 to 1146). The
median absolute SMDs for the random-effects model
and for the fixed-effect model were 0.29 (interquartile
range: 0.12 to 0.56) and 0.32 (interquartile range: 0.14 to
0.62), respectively. The subject areas of the 1068 reviews
were as follows: internal medicine, n = 404; obstetrics
and gynaecology (including paediatrics), n = 234; surgery,
n = 204; psychiatry, n = 140; anaesthesiology, n = 33; and
others, n = 53.
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I2 index
Figure 2 shows a histogram containing the I2 data. We
found, much to our surprise, that the review authors had
pooled continuous outcomes as either the MD or the
SMD, even when the I2 statistics were extremely high.
Although the median I2 was 47.6% for MD and 48.0%
for SMD, in a matched comparison, it was significantly
lower for SMD than for MD (P < 0.0001, sign test).
Percentage agreement
In the random-effects model, the median of the percent-
age agreement in which the point estimate of one trial was
included in the 95% confidence interval of the meta-
analytically pooled estimate of the remaining trials was
46.7% of the reviews if we used the SMD and 44.5% if we
used the MD (P < 0.0001, sign test). In the fixed-effect
model, the respective figures were 27.8% and 31.9% for
the SMD and the MD, respectively (P < 0.0001).
The same trend was observed when we recalculated the
percentage agreements by simulating a situation where
the review authors limited the pooling to moderately het-
erogeneous (I2 index of both MD and SMD, <60%) or to
only slightly heterogeneous (I2 index of both MD and
SMD, <30%) instances (Table 1). In each scenario, the
SMD always outperformed the MD in terms of percentage
agreement: the random-effects SMD showed the highest
agreement of 59.8% when we limited the meta-analyses to
cases for which the I-2 index of both the MD and the
SMD was less than 30%.
Z-score
If one of the statistics was statistically more heteroge-
neous than another, it would be meaningless to discuss
their relative detection power. To discuss the statistical
power, we compared the Z-score of the MD with that ofFigure 2 Histogram of I2 index for MD and SMD.the SMD using the sign test only when the I2 indices of
both the MD and the SMD were less than 30%, i.e. less
than moderate according to the proposed interpretative
guide [1].
In the random-effects model, the median absolute Z-
score for the MD was significantly higher than that for
the SMD (1.59 vs. 1.61, P = 0.007, sign test). In the fixed-
effect model, the median Z-score for the MD was again
significantly higher than that for the SMD (1.60 vs. 1.63,
P < 0.0001). However, when the statistical significance
was compared at a conventional P-value of less than
0.05, no differences in the percentage of “statistically sig-
nificant” findings were observed between MD or SMD
in either the random-effects or the fixed-effect model
(P = 1.00 and P = 0.65, respectively, McNemar test)
(Table 2).
Discussion
We empirically examined 1068 reviews from the Cochrane
Database of Systematic Reviews. The I2 index, an index of
heterogeneity, was significantly smaller when the meta-
analysed results were expressed in terms of the SMD, ra-
ther than the MD. When each one of the included RCT
was compared against the pooled results of the remaining
RCTs in each meta-analysis, the SMD showed a signifi-
cantly greater percentage agreement than the MD in both
the random-effects and the fixed-effect models for all de-
grees of heterogeneity. On the other hand, no statistically
significant difference was found in terms of statistical
power for identifying significant results between the MD
and the SMD in either the random-effects or the fixed-
effect model.
Our research agrees with one previous study regarding
heterogeneity and statistical power. This previous study
examined a relatively new index of effect, known as the
ratio of means, for analysing continuous outcomes in
Table 1 Percentage agreement for the results of a trial to be predicted by the meta-analysed results of the remaining
studies in the Cochrane reviews
Random-effects model Fixed-effect model
No. of reviews MD SMD P-value, sign test MD SMD P-value, sign test
All reviews 1068 44.5% 46.7% <0.0001 27.8% 31.9% <0.0001
I-squared of both MD and SMD <60% 560 50.0% 52.9% 0.0004 44.0% 47.9% <0.0001
I-squared of both MD and SMD <30% 357 55.3% 59.8% <0.0001 53.0% 57.8% <0.0001
The average percentages are weighted by the number of included RCTs.
Table 2 “Statistically significant” findings for treatment
effect in Cochrane reviews only when I2 of both MD and





N (%) N (%)
Both significant 164 (45.9) 168 (47.1)
MD significant but SMD non-significant 8 (2.2) 8 (2.2)
MD non-significant but SMD significant 11 (3.1) 9 (2.5)
Both non-significant 174 (48.7) 172 (48.2)
P = 0.647 in random-effects model and P = 1.000 in fixed-effect model,
according to the McNemar test.
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ous outcomes, namely the MD and the SMD. Conse-
quently, the study examined only the meta-analyses
where the ratio of means could be calculated, and it
further limited the analyses to those meta-analyses con-
taining five or more studies and examined the random-
effects model only. However, the study also found that
the P-value did not statistically differ between the MD
and the SMD and that the SMD was less heterogeneous
(defined by P < 0.1 for the Q statistic) than the MD
[17,18]. When we conducted sensitivity analyses using
our dataset by including only the meta-analyses that
contained five or more studies, the results were also
similar.
The percentage agreement figures for continuous out-
comes, either in terms of MD or SMD, found in our
study appeared to be very low, even when the associated
I2 index was reasonably low. Clinicians and researchers
must therefore be advised to use the most generalizable
index of effectiveness, while keeping in mind that the ac-
tual degrees of expected overlap may not be as high as
one would expect. We found a 5-percentage point differ-
ence in the degree of expected agreement when the re-
sults were expressed as the SMD vs. when they were
presented as the MD; this difference was clinically
meaningful and non-negligible.
Much to our surprise, however, the Cochrane authors
often pooled their continuous outcomes as the MD and/
or the SMD, even when the I2 statistics suggested ex-
treme heterogeneity. While it is true that meta-analyses
of continuous outcomes tend to be associated with a
greater I2 value than those of dichotomous outcomes be-
cause of the former’s greater statistical power, the
generalizability of such meta-analytic results would be
highly suspected when the I2 values are as high as 80%
or 90%.
The comparison of statistical power in the context of
greater heterogeneity merits a comment. In this research,
we found that the SMD was more generalizable and less
heterogeneous than the MD and that there was no signifi-
cant difference in statistical power between the MD and
the SMD. However, strictly and logically speaking, if one
statistic is statistically less generalizable and more hetero-
geneous than another, it would be meaningless to discusstheir relative detection power. To discuss statistical power,
a high percentage agreement and a low heterogeneity are
essential.
As we outlined in the Introduction, whether the MD
or the SMD is more clinically preferable as a summary
index of meta-analyses of continuous outcomes remains
controversial. When the outcome is measured in the
same natural unit, such as the amount of bleeding or the
number of days of hospitalisation, the MD is definitely
better than the SMD from the viewpoint of interpretabil-
ity. However, our studies have suggested that the SMD
may be preferable than the MD from the viewpoint of
generalizability. When the outcome is measured using
the same patient-reported outcome (PRO) measure, such
as the Hamilton Rating Scale for Depression [19], the
Short-Form 36 Quality of Life Questionnaire [20], or the
Severity Scoring of Atopic Dermatitis [21], even though
all the outcomes are measured in the same unit, the su-
perior interpretability of the SMD is not guaranteed un-
less most clinicians are very familiar with that scale. And
for many clinicians in most fields of medicine, such uni-
versally known and used PRO instruments are probably
rare to non-existent. In such instances, the SMD might
be more interpretable than the MD for two reasons.
Firstly, the SMD can be interpreted using a general rule
of thumb reported by Cohen, in which an SMD of 0.2
represents a small effect, an SMD of 0.5 represents a
medium effect, and an SMD of 0.8 or larger represents a
large effect [2]. Second, the SMD can be directly and
easily converted to a “number needed to treat” if the
control event can be assumed [22,23]. In all these
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more generalizable than the MD.
There is another way to increase interpretability of
continuous outcomes. When the minimal important
change (MIC) is known, various methods have been pro-
posed to facilitate the interpretability of continuous out-
comes [24], including conversion to MIC units and
dichotomisation using the MIC threshold. Each has its
own advantages and disadvantages, and a comprehensive
discussion of their relative merits is out of the realm of
the present study. Unfortunately, the MIC is often either
not known or, if known, may not be very precise for
most of the existing PRO measures.
Finally, SMD may have another important limitation.
Because its value derives from the difference in the
means between the treatment and control divided by
their SD, if variability of the patients is artificially or ac-
cidentally reduced, SMD would be overestimated; and if
its variability is increased, SMD would be underesti-
mated [25]. However, we think that our results concern-
ing the greater generalizability of SMD have partially
resolved such concerns because, despite the variability in
the SD across trials, SMD had better external applicabil-
ity and can therefore be said to have been less vulnerable
to over- or underestimation. However, the above men-
tioned possibility of too small or too large SD, and cor-
respondingly overestimated or underestimated SMD,
should always be borne in mind in interpreting SMD.
Our research has two limitations. Firstly, we did not
consider the influences of multiple comparisons in our
analyses. However, even if we corrected the alpha level
from 0.05 to 0.0042 using the Bonferroni method be-
cause we made 12 comparisons, only the difference in
the absolute Z-score in the random-effects model would
lose its significance; all the other results would not change.
Secondly we did not categorize the nature of the continu-
ous outcomes. It is possible that subjective continuous
outcomes may be more prone to unstable measurement
and hence be more heterogeneous than objective continu-
ous outcomes. How generalizability and power may be in-
fluenced by such differences in continuous outcomes will
be an important research topic in the future.
Conclusions
When generalizability matters, SMD may be more pre-
ferred than MD as a summary measure. In order to in-
crease interpretabillity, SMD can then be supplemented by
reporting of MD or some other proposed measures [24].
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